Ana Sayfa | Amaç ve Kapsam | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | İletişim  
2018, Cilt 16, Sayı 1, Sayfa(lar) 025-031
[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Biochemical Markers in Early Period Doxorubicin-Fluoxetine Cardiotoxicity Doksorubisin-fluoksetin kardiyotoksisite
Gül Özbey1, Selvinaz Dalaklıoğlu1, Sebahat Özdem2, Gülbahar Uzun2, Esin Tatlı1, Nuray Erin1
1Akdeniz Üniversitesi Tıp Fakültesi, Farmakoloji Anabilim Dalı, Antalya, Türkiye
2Akdeniz Üniversitesi Tıp Fakültesi, Biyokimya Anabilim Dalı, Antalya, Türkiye
Keywords: Anthracyclines; antidepressant agents; adverse effects

Aim: Doxorubicin (DOXO) is a highly effective and extensively prescribed anticancer antracycline drug, however, its use is limited by multidrug resistance and dose-dependent cumulative cardiotoxicity. Administration of DOXO with widely used antidepressan fluoxetine (FLU) is one of the treatment strategies for multidrug resistance. In this study, we aimed the investigation of FLU-DOXO combination on biochemical cardiotoxicity markers.

Material and Method: Balb-c mice divided 4 group and treated 6 weeks: (1) control (serum physiologic), (2) FLU (0.5 mg/kg/day), (3) DOXO (cumulative dose 12 mg/kg), (4) FLU (0.5 mg/kg/day) ve DOXO (cumulative dose 12 mg/kg).

Results: Regarding to our results, FLU-DOXO combination increased serum high sensitivity Troponin T (hsTnT) levels. While DOXO treatment increased serum aspartate aminotransferase (AST) and cardiac total oxidant capacity (TOS), serum alanine aminotransferase (ALT), lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) levels were unchanged.

Conclusion: Administration of DOXO with FLU may cause early stage cardiotoxicity which is determined by hsTnT.


[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Ana Sayfa | Amaç ve Kapsam | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | İletişim